Showing results (1711-1720 of 1,960) with videos related to

Sort By:
Pageof 196
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2017
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung CancerMartin Reck, Normand Blais, Erzsebet Juhasz, et al.
Blood|October 17, 2014
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing proceduresDavid Garcia, John H Alexander, Lars Wallentin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Bowel perforation in intestinal lymphoma: incidence and clinical featuresR Vaidya, T M Habermann, J H Donohue, et al.
Transplantation|October 8, 2020
Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center ExperienceCarla Leal Moreira, M Hasib Sidiqi, Francis K Buadi, et al.
Cell Metabolism|August 27, 2024
Serine and glycine physiology reversibly modulate retinal and peripheral nerve functionEsther W Lim, Regis J Fallon, Caleb Bates, et al.
The American Journal of Gastroenterology|December 20, 2022
Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort-Results of an International Multicenter Randomized Controlled TrialRichard Gearry, Shin Fukudo, Giovanni Barbara, et al.
Hematological Oncology|June 11, 2016
FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohortsHervé Ghesquières, Beth R Larrabee, Corinne Haioun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II studyGrzegorz S Nowakowski, Betsy LaPlant, William R Macon, et al.
British Journal of Haematology|March 10, 2026
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypesGeorge A Cholack, Raphael Mwangi, Prokop Vodička, et al.
The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Pageof 196